PL4069199T3 - Stałe Formulacje Farmaceutyczne 6-(2-Chloro-6-Metylopirydyn-4-Ylo)-5-(4-Fluorofenylo)-1,2,4-Triazyno-3-Aminy - Google Patents
Stałe Formulacje Farmaceutyczne 6-(2-Chloro-6-Metylopirydyn-4-Ylo)-5-(4-Fluorofenylo)-1,2,4-Triazyno-3-AminyInfo
- Publication number
- PL4069199T3 PL4069199T3 PL20819676.6T PL20819676T PL4069199T3 PL 4069199 T3 PL4069199 T3 PL 4069199T3 PL 20819676 T PL20819676 T PL 20819676T PL 4069199 T3 PL4069199 T3 PL 4069199T3
- Authority
- PL
- Poland
- Prior art keywords
- methylpyridin
- triazin
- fluorophenyl
- chloro
- amine
- Prior art date
Links
- NCWQLHHDGDXIJN-UHFFFAOYSA-N 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine Chemical compound ClC1=NC(C)=CC(C=2C(=NC(N)=NN=2)C=2C=CC(F)=CC=2)=C1 NCWQLHHDGDXIJN-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962942417P | 2019-12-02 | 2019-12-02 | |
| PCT/EP2020/084160 WO2021110697A1 (en) | 2019-12-02 | 2020-12-01 | Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4069199T3 true PL4069199T3 (pl) | 2024-06-10 |
Family
ID=73698812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20819676.6T PL4069199T3 (pl) | 2019-12-02 | 2020-12-01 | Stałe Formulacje Farmaceutyczne 6-(2-Chloro-6-Metylopirydyn-4-Ylo)-5-(4-Fluorofenylo)-1,2,4-Triazyno-3-Aminy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12502355B2 (pl) |
| EP (1) | EP4069199B1 (pl) |
| JP (1) | JP7731883B2 (pl) |
| KR (1) | KR20220109430A (pl) |
| CN (1) | CN114727963B (pl) |
| AR (1) | AR120653A1 (pl) |
| AU (1) | AU2020395495B2 (pl) |
| BR (1) | BR112022010626A2 (pl) |
| CA (1) | CA3162154A1 (pl) |
| ES (1) | ES2977281T3 (pl) |
| IL (1) | IL293268A (pl) |
| MX (1) | MX2022006662A (pl) |
| MY (1) | MY207909A (pl) |
| PL (1) | PL4069199T3 (pl) |
| TW (1) | TWI870511B (pl) |
| WO (1) | WO2021110697A1 (pl) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20130814A1 (es) | 2006-08-30 | 2013-08-08 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
| US8809525B2 (en) | 2010-02-05 | 2014-08-19 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
| CN102985072A (zh) | 2010-04-20 | 2013-03-20 | 希普拉有限公司 | 药物组合物 |
| EA028009B1 (ru) | 2013-01-22 | 2017-09-29 | Ф.Хоффманн-Ля Рош Аг | Фармацевтическая композиция с улучшенной биодоступностью |
| WO2015152433A1 (en) | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| CA2976811C (en) | 2015-03-10 | 2023-06-27 | Shionogi Inc. | Solid dispersions of ospemifene |
| EP3641812A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| IL281802B2 (en) * | 2018-09-27 | 2025-10-01 | iTeos Belgium SA | Use of an ENT family transporter inhibitor in cancer treatment and its combination with an adenosine receptor antagonist |
-
2020
- 2020-12-01 PL PL20819676.6T patent/PL4069199T3/pl unknown
- 2020-12-01 CN CN202080079856.6A patent/CN114727963B/zh active Active
- 2020-12-01 WO PCT/EP2020/084160 patent/WO2021110697A1/en not_active Ceased
- 2020-12-01 AU AU2020395495A patent/AU2020395495B2/en active Active
- 2020-12-01 KR KR1020227022040A patent/KR20220109430A/ko active Pending
- 2020-12-01 US US17/756,720 patent/US12502355B2/en active Active
- 2020-12-01 IL IL293268A patent/IL293268A/en unknown
- 2020-12-01 ES ES20819676T patent/ES2977281T3/es active Active
- 2020-12-01 JP JP2022532676A patent/JP7731883B2/ja active Active
- 2020-12-01 MX MX2022006662A patent/MX2022006662A/es unknown
- 2020-12-01 CA CA3162154A patent/CA3162154A1/en active Pending
- 2020-12-01 MY MYPI2022002810A patent/MY207909A/en unknown
- 2020-12-01 EP EP20819676.6A patent/EP4069199B1/en active Active
- 2020-12-01 BR BR112022010626A patent/BR112022010626A2/pt unknown
- 2020-12-02 AR ARP200103346A patent/AR120653A1/es unknown
- 2020-12-02 TW TW109142344A patent/TWI870511B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020395495A1 (en) | 2022-07-14 |
| TWI870511B (zh) | 2025-01-21 |
| EP4069199A1 (en) | 2022-10-12 |
| US20230000775A1 (en) | 2023-01-05 |
| AU2020395495B2 (en) | 2024-05-09 |
| WO2021110697A1 (en) | 2021-06-10 |
| CN114727963B (zh) | 2024-12-27 |
| IL293268A (en) | 2022-07-01 |
| ES2977281T3 (es) | 2024-08-21 |
| JP7731883B2 (ja) | 2025-09-01 |
| CN114727963A (zh) | 2022-07-08 |
| TW202133859A (zh) | 2021-09-16 |
| EP4069199B1 (en) | 2024-01-17 |
| BR112022010626A2 (pt) | 2022-08-16 |
| CA3162154A1 (en) | 2021-06-10 |
| JP2023505128A (ja) | 2023-02-08 |
| KR20220109430A (ko) | 2022-08-04 |
| MY207909A (en) | 2025-03-27 |
| US12502355B2 (en) | 2025-12-23 |
| MX2022006662A (es) | 2022-07-05 |
| AR120653A1 (es) | 2022-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| MY186908A (en) | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | |
| PH12017502431A1 (en) | Pharmaceutical formulations comprising tenofovir and emtrictabine | |
| NZ733125A (en) | Isoquinoline compounds for the treatment of hiv | |
| MX2020011478A (es) | Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos. | |
| SG11202100076RA (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| HK1254343A1 (zh) | 药物制剂 | |
| MX2022001655A (es) | Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). | |
| JOP20170104A1 (ar) | مشتقات فنيل تريازول مستبدلة بأميد واستخدامها | |
| SG11202103057RA (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| EP3248603A4 (en) | Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient | |
| EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
| PL4069199T3 (pl) | Stałe Formulacje Farmaceutyczne 6-(2-Chloro-6-Metylopirydyn-4-Ylo)-5-(4-Fluorofenylo)-1,2,4-Triazyno-3-Aminy | |
| WO2018211323A8 (en) | Heterocyclic compounds for the treatment of disease | |
| MX2018009948A (es) | Formulaciones de oritavancina. | |
| MX2021014918A (es) | Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6. | |
| IL288577A (en) | Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide | |
| MX2021003064A (es) | Formas cristalinas de 6-(1-acriloilpiperidin-4-il)-2-(4-fenoxifeni l)nicotinamida. |